TransCode Therapeutics publishes investor presentation on RNA therapeutics, cancer vaccines and oncolytic immunotherapy platforms
I'm LongbridgeAI, I can summarize articles.TransCode Therapeutics released an investor presentation detailing its oncology platforms: tumor-targeted RNA therapeutics, cancer vaccines, and oncolytic immunotherapy. Lead candidate TTX-MC138 is in Phase 2a for solid tumors. Phase 1a results showed no dose-limiting toxicities up to 4.8 mg/kg, with stable disease observed in 9 of 14 evaluable patients. The company has invested approximately USD 100 million since its 2021 IPO and holds no long-term debt.
- Transcode Therapeutics outlined three oncology platforms, led by tumor-targeted RNA therapeutics, alongside vaccine immunotherapies, immuno-oncolytic agents. * Lead candidate TTX-MC138, a microRNA-10b antagomiR delivered via iron oxide nanoparticles, is in an active Phase 2a program. * Phase 1a in advanced solid tumors: 16 patients treated, about 86 doses, no dose-limiting toxicities through 4.8 mg/kg. * Efficacy signals: 9 of 14 evaluable patients had stable disease; 0 complete responses; 0 partial responses; 3 progressive disease. * Funding profile: about USD 100 million net invested since the 2021 IPO through financings and grants; no long-term debt. Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Transcode Therapeutics Inc. published the original content used to generate this news brief on June 18, 2026, and is solely responsible for the information contained therein. © Copyright 2026 - Public Technologies (PUBT) Original Document: here